Gainers
- Tevogen Bio Holdings TVGN stock rose 89.7% to $0.72 during Friday's after-market session. The market value of their outstanding shares is at $122.8 million.
- Allakos ALLK stock rose 5.75% to $0.69. The market value of their outstanding shares is at $61.2 million.
- Unicycive Therapeutics UNCY stock rose 5.4% to $0.39. The company's market cap stands at $36.7 million.
- Cara Therapeutics CARA shares increased by 5.02% to $0.26. The company's market cap stands at $14.4 million.
- Protagenic Therapeutics PTIX shares rose 4.99% to $0.54. The company's market cap stands at $2.3 million.
- Immunome IMNM shares moved upwards by 4.98% to $12.84. The market value of their outstanding shares is at $771.1 million.
Losers
- Akanda AKAN stock fell 8.4% to $0.95 during Friday's after-market session. The market value of their outstanding shares is at $2.7 million.
- Dogwood Therapeutics DWTX stock fell 7.79% to $3.79. The market value of their outstanding shares is at $5.0 million.
- Nexalin Technology NXL shares declined by 7.56% to $0.72. The market value of their outstanding shares is at $7.6 million.
- NewGenIvf Group NIVF shares fell 7.14% to $0.91. The company's market cap stands at $9.2 million.
- BioLine Rx BLRX shares fell 6.88% to $0.45. The company's market cap stands at $36.2 million.
- Aclarion ACON stock fell 6.36% to $0.17. The company's market cap stands at $1.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ACONAclarion Inc
$7.501.21%
Edge Rankings
Momentum
6.66
Growth
N/A
Quality
N/A
Value
7.12
Price Trend
Short
Medium
Long
AKANAkanda Corp
$1.368.80%
BLRXBioLine Rx Ltd
$4.38-5.81%
DWTXDogwood Therapeutics Inc
$4.831.47%
IMNMImmunome Inc
$10.601.44%
NIVFNewGenIvf Group Ltd
$0.5700-6.25%
NXLNexalin Technology Inc
$1.07-6.96%
PTIXProtagenic Therapeutics Inc
$3.51-0.57%
TVGNTevogen Bio Holdings Inc
$1.23-0.81%
UNCYUnicycive Therapeutics Inc
$4.57-1.72%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.